Abstract:RET (rearranged during transfection) kinase, one of the receptor tyrosine kinases, plays a crucial role in the development of the human nervous system. It is also involved in various cell signaling networks responsible for the normal cell division, growth, migration, and survival. Previously reported clinical studies revealed that deregulation or aberrant activation of RET signaling can cause several types of human cancer. For example, medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia (MEN2A, MEN2B) occur due to sporadic mutation or germline RET mutation. A number of RET kinase inhibitors have been approved by the FDA for the treatment of cancer, such as cabozantinib, vandetanib, lenvatinib, and sorafenib. However, each of these drugs is a multikinase inhibitor. Hence, RET is an important therapeutic target for cancer drug design. In this work, we have performed various molecular modelling studies, such as molecular docking and dynamics simulation for the most active compound of the pyrazole series as RET kinase inhibitors. Furthermore, molecular mechanics Poisson–Boltzmann surface area (MM/PBSA) free energy calculation and 3-dimensional quantitative structure–activity relationship (3D-QSAR) were performed using g_mmpbsa and SYBYL-X 2.1 package. The results of this study revealed the crucial binding site residues at the active site of RET kinase and contour map analysis showed important structural characteristics for the design of new highly active inhibitors. Therefore, we have designed ten RET kinase inhibitors, which showed higher inhibitory activity than the most active compound of the series. The results of our study provide insights to design more potent and selective RET kinase inhibitors.

Synthesis and Structure–activity Relationship Study of Pyrazolo[3,4-D]pyrimidines As Tyrosine Kinase RET Inhibitors

Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation

Structural Optimization and Structure-Activity Relationship Studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine Derivatives As a New Class of Inhibitors of RET and Its Drug Resistance Mutants.

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Discovery of 3,5-Diaryl-1h-pyrazol-based Ureas As Potent RET Inhibitors.

Discovery of 4-Chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides As Novel RET Kinase Inhibitors

The Synthesis and Bioactivity of Pyrrolo[2,3-D]pyrimidine Derivatives As Tyrosine Kinase Inhibitors for NSCLC Cells with EGFR Mutations.

Design, Synthesis and Biological Evaluation of 4-Phenoxy- Pyridine/Pyrimidine Derivatives as Dual VEGFR-2/c-Met Inhibitors

1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1h-pyrazole-4-carboxamide Derivatives As New Rearranged During Transfection (RET) Kinase Inhibitors Capable of Suppressing Resistant Mutants in Solvent-Front Regions

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.

Pyridazinone Derivatives Displaying Highly Potent and Selective Inhibitory Activities Against C-Met Tyrosine Kinase.

Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors

Pyrrolo[2,3-b]pyridine Derivatives As Potent Bruton's Tyrosine Kinase Inhibitors.

Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors

Discovery of 4-Methyl-n-(4-((4-methylpiperazin- 1-Yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1h-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide As a Potent Inhibitor of RET and Its Gatekeeper Mutant

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor

Design, Synthesis and Biological Evaluation of Novel 3-Substituted Pyrazolopyrimidine Derivatives As Potent Bruton’s Tyrosine Kinase (BTK) Inhibitors